Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2d75b8ce41548dcbed9c967b77e6887 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-29 |
filingDate |
2006-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34b2c8c8edb6ec1bfaefc2f91f376eed |
publicationDate |
2007-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2621264-A1 |
titleOfInvention |
Parathyroid hormone analogues and methods of use |
abstract |
The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 µg to 60 µg, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105249463-A |
priorityDate |
2005-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |